Physician profile
Morris E Brown
NPI 1033161427
$2,208.09
in general payments reported to CMS, 2019-2025
29 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,154 · 2020: $199 · 2021: $93.65 · 2022: $159 · 2023: $292 · 2024: $122 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $234.38 | 2019-2020 | |
| Corcept Therapeutics | $220.49 | 2019 | |
| Edwards Lifesciences Corporation | $212.56 | 2022-2023 | Mitris Resilia Mitral Valve |
| Getinge USA Sales, LLC | $164.56 | 2019-2023 | Vasoview Hemopro 2 |
| Abbott Laboratories | $159.60 | 2019-2025 | Navitor |
| Novo Nordisk INC | $141.98 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $127.91 | 2019-2025 | |
| Boston Scientific Corporation | $123.02 | 2019-2023 | Varithena Administration Pack |
| Senseonics, Incorporated | $123.00 | 2019 | |
| Radius Health, INC. | $122.16 | 2024 | Tymlos |
| Tandem Diabetes Care, INC. | $120.07 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Mannkind Corporation | $77.27 | 2021 | |
| Companion Medical, INC. | $54.25 | 2019 | |
| Amarin Pharma, INC. | $36.41 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $36.34 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $32.93 | 2019-2020 | |
| Gilead Sciences, INC. | $32.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $26.26 | 2019-2020 | |
| Pfizer INC. | $18.90 | 2019 | |
| Shire North American Group INC | $18.78 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $16.99 | 2019 | |
| Harmony Biosciences LLC | $16.49 | 2020 | |
| Insulet Corporation | $15.81 | 2020 | |
| Dynavax Technologies Corporation | $15.38 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $15.31 | 2019 | |
| Merck Sharp & Dohme LLC | $11.86 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.16 | 2019 | |
| Vivus LLC | $11.16 | 2019 | |
| Medtronic Vascular, INC. | $11.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morris Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.